Nanoformulated SOD1 Ameliorates the Combined NASH and Alcohol-Associated Liver Disease Partly via Regulating CYP2E1 Expression in Adipose Tissue and Liver.

Nanoformulated SOD1 Ameliorates the Combined NASH and Alcohol-Associated Liver Disease Partly via Regulating CYP2E1 Expression in Adipose Tissue and Liver. Am J Physiol Gastrointest Liver Physiol. 2020 Jan 13;: Authors: Gopal T, Kumar N, Perriotte-Olson C, Casey CA, Donohue TM, Harris EN, Talmon G, Kabanov AV, Saraswathi V Abstract Enhanced free fatty acid (FFA) flux from adipose tissue (AT) to liver plays an important role in the development of non-alcoholic steatohepatitis (NASH) and alcohol-associated liver disease (AALD). We determined the effectiveness of nanoformulated superoxide dismutase 1 (Nano) in attenuating liver injury in a mouse model exhibiting a combination of NASH and AALD. Male C57BL6/J mice were fed a chow diet (CD) or a high fat diet (HF) for 10 wk followed by pair-feeding the Lieber-DeCarli control (control) or ethanol (ET) diet for 4 wk. Nano was administered once every other day for the last 2 wk of ET feeding. Mice were divided into: 1) CD+control diet (CD+Cont), 2) High fat diet (HF)+control diet (HF+Cont), 3) HF+Cont+Nano, 4) HF+ ET diet (HF+ET), and 5) HF+ET+Nano. The total fat mass, visceral AT mass (VAT), and VAT perilipin 1 content were significantly lower only in HF+ET-fed mice but not in HF+ET+Nano-treated mice compared to controls. The HF+ET-fed mice showed an upregulation of VAT CYP2E1 protein, and Nano abrogated this effect. We noted a significant rise in plasma FFAs, ALT, and MCP-1 in HF+ET-fed mic...
Source: American Journal of Physiology. Gastrointestinal and Liver Physiology - Category: Physiology Authors: Tags: Am J Physiol Gastrointest Liver Physiol Source Type: research